Pharming Group has sawed off its gene therapy collaboration with Orchard Therapeutics, a decision that will see the end of a preclinical hereditary angioedema (HAE) program.. Netherlands-based ...

Pharming Group (NASDAQ: NASDAQ:PHAR) stands as a globally recognized biotechnology firm based in the Netherlands.It is best known for its unique approach to addressing rare and genetic diseases ...

The disease was first characterized in 2013 and can now be diagnosed with genetic testing. According to Pharming, APDS affects an estimated 1 million to 2 million people worldwide.

Pharming Group reports third quarter 2023 financial results. Third quarter 2023 revenues increased 23% to US $66.7 million, ... genetic testing family members of APDS patients, ...

The U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the Dutch company said.

Pharming Group (PHGUF) reported a 42% increase in total revenues for Q1 2025, driven by strong sales of Ruconest and Joenja. Ruconest sales grew by 49% to $68.6 million, supported by increased ...

Pharming Group N.V., a biopharmaceutical company, ... It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease.. At ...

New methods help lift genetic uncertainty. ... This work was also supported in part through a sponsored research agreement with Pharming; the NIH (grants R37CA258829, R01CA266446, R01CA280414 ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, ...

Fabrice Chouraqui, Chief Executive Officer of Pharming, said: ... including permanent lung damage and lymphoma. 4-7 A definitive diagnosis can be made through genetic testing.